2026 Advances in Prostate Cancer Management: A Multidisciplinary Approach

This two-day course, presented by faculty from Memorial Sloan Kettering Cancer Center (MSK), will highlight the latest advances in the multidisciplinary management of prostate cancer. Through comprehensive, state-of-the-art lectures and interactive discussions, participants will engage with expert faculty spanning radiology, pathology, surgery, radiation oncology, and medical oncology to exchange insights and explore collaborative approaches to prostate cancer care.

Sessions will cover the full continuum of care, including patient evaluation and risk assessment, active surveillance, focal therapy, local and systemic therapies, and the prevention and management of treatment-related side effects. Participants will also gain insights into emerging research and innovations shaping the future of prostate cancer care, including the latest scientific discoveries and clinical advances from MSK.

This program is intended for urologists, urologic oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, and allied health professionals involved in the care of patients with prostate cancer. Participants may attend either onsite at MSK or virtually via Zoom.

Following the course, participants will receive access to an online syllabus containing recordings of the faculty presentations and PDF copies of the presentation slides.

1. Evaluate contemporary evidence and guideline recommendations for the management of localized and advanced prostate cancer, including active surveillance, focal therapy, surgery, radiation therapy, and systemic treatment options.
2. Apply clinical, pathologic, genomic, and imaging data to risk stratification and individualized treatment planning for patients across the prostate cancer disease continuum.
3. Interpret the appropriate use and clinical implications of genomic testing, biomarkers, and PSMA PET imaging to support diagnostic, prognostic, and therapeutic decision-making.
4. Compare and select evidence-based treatment strategies for patients with advanced prostate cancer, including the integration and sequencing of emerging systemic therapies.
5. Integrate multidisciplinary perspectives from urology, medical oncology, radiation oncology, radiology, and pathology to optimize patient-centered prostate cancer care and improve clinical outcomes.

Participants may attend either onsite at MSK or virtually via Zoom. Virtual participants will receive access instructions and login details prior to the program. Those planning to attend in person are encouraged to visit our Visiting Us page for information about accommodations, parking, directions, and other details to help plan their visit.

Registration Fees

• Early Rates (Available through August 13, 2026)

  • Physicians (MDs, PhDs, DOs): $500

  • Advanced Practice Providers: $350

  • Nurses and Other Healthcare Professionals: $300

  • Residents and Fellows: $100

  • Industry Professionals: Not applicable (general rates apply)*

  • MSK Employees: Complimentary**

• General Rates (After August 13, 2026)

  • Physicians (MDs, PhDs, DOs): $600

  • Advanced Practice Providers: $450

  • Nurses and Other Healthcare Professionals: $400

  • Residents and Fellows: $200

  • Industry Professionals: $1,050*

  • MSK Employees: Complimentary**

Discounted registration is available for select groups, including students, MSK alumni/affiliates, and participants from low- and lower-middle-income countries. View our Policy on Registration Discounts for more information.

For cancellation details, please review our Cancellation Policy.

*An industry professional is defined as any individual, irrespective of their provider type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company. Review our Registration Policy for Industry Professionals for more information.
**MSK employees receive complimentary registration for all CME programs by signing in with MSK credentials (SSO).

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved to offer the following credit types.

• AMA PRA Category 1 Credit(s)™

• ABIM Maintenance of Certification (MOC)

• ABS Continuous Certification (CC)

The following credits are pending approval:

• Nursing Continuing Professional Development (NCPD) Credit

MSK Course Directors 

Behfar Ehdaie, MD, MPH
Associate Attending
Urology Service 
Department of Medicine 

Michael J. Morris, MD
Steven A. Greenberg Chair in Prostate Cancer Research
Attending; Prostate Cancer Section Head
Genitourinary Oncology Service 
Department of Medicine

Himanshu Nagar, MD, MS
Director, Genitourinary Program
Manhattan Chief of External Beam Radiotherapy
Department of Radiation Oncology

A complete faculty list and agenda will be announced in August. 

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.